Vonvendi (von Willebrand factor [recombinant]) for Hemophilia | MyHemophiliaTeam

Connect with others who understand.

sign up log in
About MyHemophiliaTeam
Powered By

Vonvendi is approved by the Food and Drug Administration (FDA) for on-demand treatment and control of bleeding episodes in adults with von Willebrand disease. The technical name of Vonvendi is von Willebrand factor (recombinant).

Vonvendi is a clotting factor. Clotting factors work by supplying proteins missing in people with bleeding disorders.

How do I take it?
Prescribing information states that Vonvendi is given as an intravenous injection.

Vonvendi comes as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for Vonvendi lists common side effects including itching.

Rare but serious side effects listed for Vonvendi include life-threatening hypersensitivity reactions, thromboembolic events (dangerous blood clots), and the development of inhibitors.

For more details about this treatment, visit:


Treatment of Hemophilia – Hemophilia Federation of America

Continue with Facebook
Continue with Google
Your privacy is our priority. By continuing, you accept our Terms of Use and Privacy Policy.
Already a Member? Log in